We are independent & ad-supported. We may earn a commission for purchases made through our links.

Advertiser Disclosure

Our website is an independent, advertising-supported platform. We provide our content free of charge to our readers, and to keep it that way, we rely on revenue generated through advertisements and affiliate partnerships. This means that when you click on certain links on our site and make a purchase, we may earn a commission. Learn more.

How We Make Money

We sustain our operations through affiliate commissions and advertising. If you click on an affiliate link and make a purchase, we may receive a commission from the merchant at no additional cost to you. We also display advertisements on our website, which help generate revenue to support our work and keep our content free for readers. Our editorial team operates independently from our advertising and affiliate partnerships to ensure that our content remains unbiased and focused on providing you with the best information and recommendations based on thorough research and honest evaluations. To remain transparent, we’ve provided a list of our current affiliate partners here.

What Is a Bevacizumab Injection?

By C. K. Lanz
Updated May 17, 2024
Our promise to you
WiseGeek is dedicated to creating trustworthy, high-quality content that always prioritizes transparency, integrity, and inclusivity above all else. Our ensure that our content creation and review process includes rigorous fact-checking, evidence-based, and continual updates to ensure accuracy and reliability.

Our Promise to you

Founded in 2002, our company has been a trusted resource for readers seeking informative and engaging content. Our dedication to quality remains unwavering—and will never change. We follow a strict editorial policy, ensuring that our content is authored by highly qualified professionals and edited by subject matter experts. This guarantees that everything we publish is objective, accurate, and trustworthy.

Over the years, we've refined our approach to cover a wide range of topics, providing readers with reliable and practical advice to enhance their knowledge and skills. That's why millions of readers turn to us each year. Join us in celebrating the joy of learning, guided by standards you can trust.

Editorial Standards

At WiseGeek, we are committed to creating content that you can trust. Our editorial process is designed to ensure that every piece of content we publish is accurate, reliable, and informative.

Our team of experienced writers and editors follows a strict set of guidelines to ensure the highest quality content. We conduct thorough research, fact-check all information, and rely on credible sources to back up our claims. Our content is reviewed by subject matter experts to ensure accuracy and clarity.

We believe in transparency and maintain editorial independence from our advertisers. Our team does not receive direct compensation from advertisers, allowing us to create unbiased content that prioritizes your interests.

A bevacizumab injection is a solution administered to patients being treated for some types of cancers that have metastasized. It is given with chemotherapy to treat colorectal, lung, and kidney cancer. Glioblastoma patients whose cancer has progressed despite prior treatment may also be given a bevacizumab injection. The United States Food and Drug Administration (FDA) initially approved this treatment for metastasized breast cancer but withdrew this indication in June 2011. In the United States, this medication is marketed under the brand name Avastin®.

This medication is an antiangiogenic agent. It stops the formation of blood vessels that provide a tumor with oxygen and nutrients. This may help slow and stop tumor growth and metastization. As a result, patients are more likely to live longer.

Patients receive a bevacizumab injection through a vein. Doses are administered in a health care center by a nurse or a doctor. The first dose typically takes 90 minutes, while subsequent doses take less than an hour. Subsequent doses are administered only if no serious problems develop after receiving the first. A bevacizumab injection is usually given once every two weeks for colorectal cancer and once every three weeks for lung cancer.

In patients with metastatic colorectal cancer, this injection is part of first-line therapy with chemotherapy. It is also used with chemotherapy to treat patients with advanced nonsquamous non-small cell lung cancer. Individuals with metastatic kidney cancer take a bevacizumab injection with interferon alfa. Those with glioblastoma take these injections alone when this cancer progresses despite prior treatment.

In addition to its use as a cancer treatment, this drug may also be given to patients with wet age-related macular degeneration (AMD). AMD is a progressive eye disease that affects the patient’s ability to see straight ahead. As a result, it can become difficult to drive and read. Other eye diseases, like diabetic retinopathy, may also be treated with this medication, but in relatively smaller and cheaper doses than those required for cancer patients.

The most common side effects of a bevacizumab injection are high blood pressure and nose bleed. There are several serious and possibly fatal side effects, such as massive bleeding; perforations of the nose, stomach, and intestines; and blood clots. Major cardiovascular events, kidney damage, and wounds that are slow to heal have also been experienced by patients taking this medication. Some patients develop reversible posterior leukoencephalopathy syndrome while using bevacizumab.

Although treatment with bevacizumab injection remains available for patients with colorectal, kidney, and lung cancers, the FDA withdrew its approval of the drug for metastasized breast cancer in June 2011. The FDA based its decision on the results of required clinical trials of the medication. The results indicated that the addition of a bevacizumab injection with chemotherapy did not prolong patients’ lives and showed only a slight delay in tumor growth. This small benefit did not outweigh the increase in serious side effects experienced once the injection was added to treatment.

There is anecdotal evidence that some women with breast cancer benefited from treatment with a bevacizumab injection. Such evidence is difficult to substantiate outside the clinical trial setting, however. Doctors can continue to use the injection to treat breast cancer, but American health insurance companies are not likely pay for it. Breast cancer patients and their oncologists can consider the other available treatment options instead of Avastin®.

WiseGeek is dedicated to providing accurate and trustworthy information. We carefully select reputable sources and employ a rigorous fact-checking process to maintain the highest standards. To learn more about our commitment to accuracy, read our editorial process.

Discussion Comments

WiseGeek, in your inbox

Our latest articles, guides, and more, delivered daily.

WiseGeek, in your inbox

Our latest articles, guides, and more, delivered daily.